CD8A and osteosarcoma: And the result showed that SGLT2 inhibitor treatment further inhibited the tumor growth and promoted the infiltration of CD4+ and CD8+ T cells induced by immunotherapy (anti-PD-1) therapy in osteosarcoma (Supplementary Fig. 6).